Neurocrine Biosciences and Diurnal presented information from its neuroendocrinology pipeline at the Endocrine Society Annual Meeting, ENDO 2024, including primary data just published in The New England Journal of Medicine from its CAHtalyst Phase 3 registrational studies of crinecerfont in pediatric and adult patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. “We were thrilled to share our just published primary CAHtalyst Phase 3 data with ENDO 2024 attendees this past weekend,” said Eiry Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences. “Crinecerfont offers the potential of a long-awaited new treatment paradigm for endocrinologists in managing CAH. Our CAHtalyst Phase 3 data demonstrate the potential of crinecerfont to reduce elevated androgen levels and lower supraphysiologic glucocorticoid doses while maintaining androgen control in CAH patients of four years and older.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine Biosciences Announces CEO Retirement and Succession
- Neurocrine CEO Kevin Gorman, Ph.D to retire, Kyle Gano, Ph.D to succeed
- Neurocrine price target raised to $193 from $174 at UBS
- RBC still sees gradual uptake for Neurocrine after competitor data
- Neurocrine competitive data should be kept in perspective, says Evercore